News | Contrast Media | July 03, 2023

Switch to MR Angiography for PE Mitigated Impact of Recent Contrast Shortage

Preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage 

Preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage

Patient was found to have deep vein thrombosis. Gadolinium-enhanced MRA was performed to assess for pulmonary embolus (PE). Coronal contrast-enhanced T1-weighted images in pulmonary arterial phase (A) and low flip-angle delayed phase (B) show PE (arrows, A and B). Delayed-phase image also shows cardiac chamber (star) and ascending thoracic aorta (chevron). Multiphase acquisition of MRA during inflow and outflow of contrast agent from pulmonary arteries is in distinction to single acquisition of CTA and may facilitate obtaining optimal enhancement of pulmonary arteries. Image courtesy of AJR 


July 3, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR), preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage. 

“This single-center experience demonstrates use of pulmonary MRA as a practical substitute for pulmonary CTA in emergency settings,” concluded lead investigator Jitka Starekova, MD, from the radiology department of the University of Wisconsin in Madison.   

Starekova et al.’s study included all CTA and MRA examinations performed to exclude PE at their large academic medical center (University of Wisconsin-Madison Hospital and Clinics) from April 1 through July 31 (18 weekly periods) in:   

2019 (before the COVID-19 pandemic and contrast media shortage), 

2021 (during the pandemic, though before the shortage), 

2022 (during both the pandemic, as well as the shortage). 

To help preserve iodinated contrast media, from early May through mid-July of 2022, MRA served as the preferred test for PE diagnosis. Upon reviewing CTA and MRA reports, Starekova and her AJR colleagues estimated iodinated contrast media savings via preferential MRA usage. 

Ultimately, preferred use of pulmonary MRA to diagnosis PE among the general population conserved (from April 1 to July 31, 2022) an estimated 27 liters of iohexol (Omnipaque) 350mg/ml. During weeks 8-11, more MRA examinations (range, 45-63) than CTA examinations (range, 27-46) were performed. 

Noting their AJR accepted manuscript evaluated MRA for PE diagnosis in “an all-comer real-world setting,” the present study also includes a larger sample size in comparison to previous research. 

For more information: www.arrs.org


Related Content

News | Contrast Media

August 17, 2023 — University of Missouri School of Medicine neurologist Adnan Qureshi, MD recently led a study that ...

Home August 17, 2023
Home
News | Contrast Media

May 11, 2021 — The American Institute of Ultrasound in Medicine (AIUM) and the American Society of Echocardiography (ASE ...

Home May 11, 2021
Home
Technology | Contrast Media

July 15, 2019 — The U.S. Food and Drug Administration (FDA) has approved Gadavist injection for use in cardiac magnetic ...

Home July 15, 2019
Home
Videos | Contrast Media

Sharon Mulvagh, M.D., FASE, FACC, FRCPC, professor of medicine, division of cardiology, Dalhousie University, Halifax ...

Home June 28, 2019
Home
Feature | Contrast Media | Dave Fornell, Editor

Iodine-based contrast agents used in computed tomography (CT) and catheter-based angiography have been implicated as a ...

Home May 31, 2019
Home
News | Contrast Media

May 9, 2019 — Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety ...

Home May 09, 2019
Home
News | Contrast Media

November 30, 2018 — VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that ...

Home November 30, 2018
Home
News | Contrast Media

In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore ...

Home September 12, 2018
Home
News | Contrast Media

January 19, 2018 — Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced ...

Home January 19, 2018
Home
News | Contrast Media

September 7, 2017 — The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging ...

Home September 07, 2017
Home
Subscribe Now